New Perspectives in the Renin-Angiotensin-Aldosterone System RAAS I: Endogenous Angiotensin Converting Enzyme ACE InhibitionReportar como inadecuado




New Perspectives in the Renin-Angiotensin-Aldosterone System RAAS I: Endogenous Angiotensin Converting Enzyme ACE Inhibition - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Angiotensin-converting enzyme ACE inhibitors represent the fifth most often prescribed drugs. ACE inhibitors decrease 5-year mortality by approximately one-fifth in cardiovascular patients. Surprisingly, there are reports dating back to 1979 suggesting the existence of endogenous ACE inhibitors, which endogenous inhibitory effects are much less characterized than that for the clinically administered ACE inhibitors. Here we aimed to investigate this endogenous ACE inhibition in human sera. It was hypothesized that ACE activity is masked by an endogenous inhibitor, which dissociates from the ACE when its concentration decreases upon dilution. ACE activity was measured by FAPGG hydrolysis first. The specific dilution corrected enzyme activities significantly increased by dilution of human serum samples 23.2±0.7 U-L at 4-fold dilution, 51.4±0.3 U-L at 32-fold dilution, n = 3, p = 0.001, suggesting the presence of an endogenous inhibitor. In accordance, specific enzyme activities did not changed by dilution when purified renal ACE was used, where no endogenous inhibitor was present 655±145 U-L, 605±42 U-L, n = 3, p = 0.715, respectively. FAPGG conversion strongly correlated with angiotensin I conversion suggesting that this feature is not related to the artificial substrate. Serum samples were ultra-filtered to separate ACE MW: 180 kDa and the hypothesized inhibitor. Filtering through 50 kDa filters was without effect, while filtering through 100 kDa filters eliminated the inhibiting factor ACE activity after <100 kDa filtering: 56.4±2.4 U-L, n = 4, control: 26.4±0.7 U-L, n = 4, p<0.001. Lineweaver-Burk plot indicated non-competitive inhibition of ACE by this endogenous factor. The endogenous inhibitor had higher potency on the C-terminal active site than N-terminal active site of ACE. Finally, this endogenous ACE inhibition was also present in mouse, donkey, goat, bovine sera besides men increasing of specific ACE activity from 4-fold to 32-fold dilution: 2.8-fold, 1.7-fold, 1.5-fold, 1.8-fold, 2.6-fold, respectively. We report here the existence of an evolutionary conserved mechanism suppressing circulating ACE activity, in vivo, similarly to ACE inhibitory drugs.



Autor: Miklós Fagyas, Katalin Úri, Ivetta M. Siket, Andrea Daragó, Judit Boczán, Emese Bányai, István Édes, Zoltán Papp, Attila

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados